NeuroDiscovery makes market debut
Monday, 15 August, 2005
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) listed today on the Australian Stock Exchange at AUD$0.21, one cent above its issue price of $0.20.
NeuroDiscovery's IPO raised AUD$1.5 million through the issue of 36 million shares, and the company has finalised purchase of UK-based NeuroSolutions, which has a mature pipeline of programs for the treatment of pain.
"We are very pleased that we have been able to buy NeuroSolutions and welcome the University of Warwick as our major shareholder. As this is the first successful spin-out of the university we look forward to working with them in the next few years." said NeuroDiscovery chairman David McAuliffe.
At the time of writing, shares were trading at $0.20.
Scientists complete final chromosome in synthetic yeast genome
The synthetic chromosome includes features that enable researchers to generate genetic diversity...
Self-destructing vaccine protects against TB in monkeys
A self-destructing vaccine administered intravenously provides additional safety and protection...
New drug to prevent migraine claimed to work straight away
People taking atogepant showed improvement on assessments of how much migraine impaired their...
